Form 8-K - Current report:
SEC Accession No. 0001493152-21-020512
Filing Date
2021-08-18
Accepted
2021-08-18 08:27:50
Documents
13
Period of Report
2021-08-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52434
2 ex4-1.htm EX-4.1 70271
  Complete submission text file 0001493152-21-020512.txt   307222

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE provectusbiocom-20210813.xsd EX-101.SCH 3069
4 XBRL LABEL FILE provectusbiocom-20210813_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE provectusbiocom-20210813_pre.xml EX-101.PRE 22377
6 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3326
Mailing Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932
Business Address 10025 INVESTMENT DRIVE SUITE 250 KNOXVILLE TN 37932 865-769-4011
PROVECTUS BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000315545 (see all company filings)

EIN.: 900031917 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36457 | Film No.: 211185061
SIC: 2834 Pharmaceutical Preparations